Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Intuitive Surgical (ISRG) and Thermo Fisher (TMO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), Intuitive Surgical (ISRG – Research Report) and Thermo Fisher (TMO – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AbbVie (ABBV)
Piper Sandler analyst David Amsellem reiterated a Buy rating on AbbVie today and set a price target of $289.00. The company’s shares closed last Friday at $223.01.
According to TipRanks.com, Amsellem is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $252.64 average price target, a 14.6% upside from current levels. In a report issued on January 19, Berenberg Bank also maintained a Buy rating on the stock with a $275.00 price target.
See today’s best-performing stocks on TipRanks >>
Intuitive Surgical (ISRG)
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Intuitive Surgical, with a price target of $620.00. The company’s shares closed last Friday at $504.22.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intuitive Surgical with a $652.73 average price target, representing a 28.8% upside. In a report issued on January 30, TD Cowen also initiated coverage with a Buy rating on the stock with a $660.00 price target.
Thermo Fisher (TMO)
CMB International Securities analyst Jill Wu maintained a Buy rating on Thermo Fisher today and set a price target of $670.00. The company’s shares closed last Friday at $578.61.
According to TipRanks.com, Wu is a 5-star analyst with an average return of
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $675.79, a 16.2% upside from current levels. In a report issued on January 29, TipRanks – PerPlexity also upgraded the stock to Buy with a $672.00 price target.
